Evidence map›Paper›PMID 29552121›Full record

ArticleOncology letters2018

Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression.

Zirong Pan, Jianmin Zhuang, Chenghong Ji, Zhezhen Cai, Weijia Liao, Zhengjie Huang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zirong PanDepartment of General Surgery, Xiamen Haicang Hospital, Xiamen, Fujian 361026, P.R. China.
Jianmin ZhuangDepartment of General Surgery, Xiamen Haicang Hospital, Xiamen, Fujian 361026, P.R. China.
Chenghong JiDepartment of General Surgery, Xiamen Haicang Hospital, Xiamen, Fujian 361026, P.R. China.
Zhezhen CaiDepartment of General Surgery, Xiamen Haicang Hospital, Xiamen, Fujian 361026, P.R. China.
Weijia LiaoDepartment of General Surgery, Xiamen Haicang Hospital, Xiamen, Fujian 361026, P.R. China.
Zhengjie HuangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China.
Xiamen Chang Gung Hospital · CNFirst Affiliated Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morbidity and mortality owing to hepatocellular carcinoma (HCC), the most common primary liver cancer, has increased in recent years. Curcumin is a polyphenol compound that has been demonstrated to exert effective antiangiogenic, anti-inflammatory, antioxidant, and antitumor effects. However, its clinical effects in HCC remain elusive. The main aim of the present study was to determine the antiangiogenic effects of curcumin in HCC. H22HCC cells were treated with different concentrations of curcumin

Indexed as

anti-angiogenicchemotherapycurcuminhepatocellular carcinomapolyphenol compoundvascular endothelial growth factor

Identifiers

PMID29552121
PMCPMC5840714
OpenAlexW2789132639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.